+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)

  • ID: 4720463
  • Report
  • November 2018
  • Region: Global
  • 52 pages
  • GlobalData


  • Afimmune
  • BMS
  • DeuteRx
  • HighTide Biopharma
  • Naia
  • Second Genome
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)


"Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)", briefings contain evaluations of ongoing development activities within the Non-Alcoholic Steatohepatitis (NASH) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report -
  • Phase II NCT02787304 trial has been discontinued, and the future of SHP626 (volixibat) in NASH is currently uncertain
  • Topline results for Phase IIb NATIVE trial of lanifibranor in NASH are currently expected in H1 2020 (delayed from the original schedule of mid-2018 due to slow patient enrollment)
  • Medicinova will likely initiate a Phase IIb trial for MN-001 with biopsy-based endpoints, which could begin at any time
The report comprises three sections -

Executive Summary
  • Contains analysis of key market events that have occurred during the previous month and which have impacted the NASH landscape.
Landscape Updates
  • ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product’s lifecycle management initiatives.
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline therapies.
Pipeline Landscape
  • An overview of pipeline candidates, containing snapshots of current development status.
  • Expected drug-specific events & milestones until YE 2020.
  • Current early stage RA pipeline & candidate ‘Watch List’.
  • Timeline assumptions, including standard assumptions & drug-specific assumptions.
  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.
Reasons to Buy
  • Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
  • Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
  • Reviews ongoing lifecycle management strategies for existing players in the market
  • A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.
Note: Product cover images may vary from those shown


  • Afimmune
  • BMS
  • DeuteRx
  • HighTide Biopharma
  • Naia
  • Second Genome
  • MORE
Introduction to Sociable Pharma’s ‘Competitor Landscape’
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor ‘Direction of Travel’
Pipeline Landscape
Pipeline Summary
Note: Product cover images may vary from those shown
  • Afimmune
  • Akarna Therapeutics
  • Akero Therapeutics
  • Albireo
  • Allergan
  • Allergan (acquired from
  • Ardelyx
  • Arisaph
  • AstraZeneca
  • BHV Pharma Inc
  • Bird Rock Bio/Janssen
  • BMS
  • Boehringer Ingelheim
  • Can-Fite BioPharma
  • Celgene
  • Cempra
  • Cerenis Therapeutics
  • ChemomAb
  • Cirius Therapeutics
  • CohBar
  • ConSynance Therapeutics
  • CymaBay Therapeutics
  • DeuteRx
  • Dr. Falk Pharma GmbH
  • DURECT Corporation
  • Eli Lilly
  • Enanta
  • Galectin Therapeutics
  • Galmed
  • Gemcabene
  • Genfit
  • Gilead
  • GRI Bio
  • HighTide Biopharma
  • Immune Pharmaceuticals Inc.
  • Immuron
  • Intercept
  • INVENT Pharmaceuticals
  • Inventiva
  • Ionis Pharma-ceuticals
  • Janssen
  • Madrigal
  • MediciNova
  • Metacrine
  • Mitsubishi Tanabe
  • Naia
  • NGM Biopharmaceuticals
  • Nitto Denko
  • NorthSea Therapeutics
  • Novartis
  • Novo Nordisk
  • NuSirt BioPharma
  • Oramed
  • Pfizer
  • Poxel
  • Sanofi
  • Second Genome
  • Shire
  • Sinew Pharma
  • Sucampo Pharmaceuticals
  • Synairgen
  • Taiwan Pharmaceuticals
  • Teva
  • Tiziana Life Sciences
  • Valbiotis
  • Viking Therapeutics
  • Virobay
  • Zafgen
  • Zydus Discovery
Note: Product cover images may vary from those shown